Alpine Immune Sciences stock price, funding rounds, valuation and financials

Alpine Immune Sciences has raised $49.3 m in total funding. Alpine Immune Sciences annual revenue was $9.34 m in FY 2020

$9.3 M

Alpine Immune Sciences Revenue FY, 2020
Alpine Immune Sciences Net income (FY, 2020)-27.9 M
Alpine Immune Sciences EBIT (FY, 2020)-28.7 M
Alpine Immune Sciences Cash, 31-Dec-202035 M
Get notified regarding key financial metrics and revenue changes at Alpine Immune SciencesLearn more
Banner background

Alpine Immune Sciences Funding

Summary Metrics

Founding Date

2015

Alpine Immune Sciences total Funding

$49.3 m

Alpine Immune Sciences latest funding size

$48 m

Time since last funding

6 years ago

Alpine Immune Sciences investors

Alpine Immune Sciences's latest funding round in June 2016 was reported to be $48 m. In total, Alpine Immune Sciences has raised $49.3 m

Alpine Immune Sciences Capital Raised

Embed Graph

Alpine Immune Sciences Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

492.0k3.0m1.7m705.0k1.7m9.3m

Revenue growth, %

500%(41%)

R&D expense

422.0k3.0m10.6m29.0m35.8m27.2m

General and administrative expense

441.0k1.1m6.1m8.4m9.5m10.9m

Operating expense total

863.0k4.1m16.7m37.3m45.3m38.1m

EBIT

(371.0k)(1.2m)(15.0m)(37.8m)(43.6m)(28.7m)

EBIT margin, %

(75%)(40%)(865%)(5366%)(2504%)(308%)

Interest expense

152.0k

Interest income

1.3m812.0k1.3m

Investment income

1.2m245.0k

Pre tax profit

(369.0k)(1.2m)(8.0m)(36.9m)(41.9m)(27.9m)

Income tax expense

66.0k(200.0k)(366.0k)(6.0k)

Net Income

(369.0k)(1.2m)(7.8m)(36.5m)(41.9m)(27.9m)

Alpine Immune Sciences Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

25.0m11.8m8.0m10.7m16.1m35.0m

Prepaid Expenses

432.0k36.0k1.3m1.2m1.7m1.5m

Current Assets

87.7m11.9m82.5m53.5m42.3m107.1m

PP&E

223.0k740.0k1.1m1.2m1.6m1.8m

Total Assets

87.9m12.6m85.2m54.9m54.1m144.1m

Accounts Payable

994.0k127.0k193.0k1.7m1.5m582.0k

Short-term debt

995.0k2.0m418.0k3.2m

Current Liabilities

4.4m2.4m1.9m8.1m8.7m41.2m

Long-term debt

113.0k4.0m2.2m15.9m29.4m

Total Debt

113.0k5.0m4.2m16.4m32.6m

Total Liabilities

2.5m6.3m10.3m24.6m81.9m

Common Stock

14.0k14.0k19.0k24.0k

Preferred Stock

15.0k11.5m

Additional Paid-in Capital

232.3m144.0k88.3m90.7m117.4m177.9m

Retained Earnings

(14.8m)1.6m9.4m(46.1m)(87.9m)(115.9m)

Total Equity

83.5m1.5m78.9m44.6m29.5m62.2m

Debt to Equity Ratio

0.1 x0.1 x0.1 x

Debt to Assets Ratio

0 x0.1 x0.1 x

Financial Leverage

1.1 x8.6 x1.1 x1.2 x1.8 x2.3 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

100.5m57.6m16.0m15.4m16.2m12.9m27.5m12.0m7.4m3.6m11.5m41.4m15.5m17.4m24.4m88.2m

Prepaid Expenses

569.0k996.0k501.0k480.0k843.0k263.0k129.0k884.0k1.3m1.9m1.1m939.0k1.7m5.7m2.3m1.0m

Current Assets

101.1m93.6m80.7m74.2m67.0m52.9m49.6m88.1m78.0m71.8m63.1m64.9m57.2m52.5m38.1m91.2m

PP&E

1.1m1.1m1.2m1.3m1.2m1.2m1.2m1.7m1.5m

Total Assets

101.2m93.8m80.9m74.6m67.3m53.0m49.6m90.8m80.7m73.1m64.5m67.1m70.1m64.7m49.8m102.7m

Accounts Payable

3.4m1.6m1.2m2.1m1.0m1.3m815.0k1.1m528.0k750.0k440.0k743.0k2.4m5.8m468.0k548.0k

Short-term debt

490.0k1.5m2.0m2.0m2.1m2.1m1.7m119.0k

Current Liabilities

6.1m4.5m4.6m5.9m5.2m3.8m3.6m2.7m2.9m3.4m6.9m8.8m12.6m13.7m5.1m28.2m

Long-term debt

4.5m3.6m3.1m2.6m1.7m12.1m16.2m19.9m21.8m

Total Debt

5.0m5.1m5.1m4.7m3.7m14.2m16.2m21.6m21.9m

Total Liabilities

7.8m6.8m6.6m9.5m10.5m24.7m29.9m25.0m86.5m

Common Stock

15.0k15.0k15.0k15.0k16.0k16.0k16.0k1.0k14.0k14.0k14.0k19.0k19.0k19.0k19.0k19.0k

Additional Paid-in Capital

231.3m231.6m233.0m233.8m234.7m238.4m239.0m88.0m88.9m89.4m89.9m115.0m115.7m116.6m118.4m119.7m

Retained Earnings

(136.2m)(142.3m)(156.7m)(165.2m)(172.6m)(189.2m)(192.9m)(5.1m)(14.9m)(22.8m)(34.9m)(58.5m)(70.3m)(81.8m)(93.5m)(103.4m)

Total Equity

95.1m89.4m76.4m68.7m62.1m49.2m46.1m83.0m73.9m66.5m55.0m56.6m45.4m34.8m24.9m16.2m

Debt to Equity Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0.3 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0.2 x

Financial Leverage

1.1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x1.5 x1.9 x2 x6.3 x

Alpine Immune Sciences Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(22.8m)(31.5m)(7.8m)(36.5m)(41.9m)(27.9m)

Depreciation and Amortization

66.0k241.0k388.0k468.0k578.0k

Accounts Payable

65.0k927.0k66.0k1.5m816.0k(491.0k)

Cash From Operating Activities

(19.2m)(26.3m)(16.6m)(28.4m)(35.3m)30.1m

Purchases of PP&E

(188.0k)(106.0k)(586.0k)(495.0k)(821.0k)(802.0k)

Cash From Investing Activities

(62.4m)25.3m(29.8m)32.1m16.8m(72.8m)

Long-term Borrowings

(1.0m)(1.3m)

Cash From Financing Activities

78.8m166.0k42.7m(991.0k)24.3m61.4m

Net Change in Cash

(2.8m)(788.0k)(3.7m)2.7m5.7m18.7m

Interest Paid

53.0k149.0k170.0k490.0k

Income Taxes Paid

76.0k(6.0k)

Alpine Immune Sciences Ratios

USDQ2, 2015

Financial Leverage

1.1 x